FMR1 gray-zone alleles: Association with Parkinson's disease in women?
Carriers of fragile X mental retardation 1 repeat expansions in the premutation range (55–200 CGG repeats), especially males, often develop tremor, ataxia, and parkinsonism. These neurological signs are believed to be a result of elevated levels of expanded CGG‐repeat fragile X mental retardation 1...
Saved in:
Published in | Movement disorders Vol. 26; no. 10; pp. 1900 - 1906 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15.08.2011
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Carriers of fragile X mental retardation 1 repeat expansions in the premutation range (55–200 CGG repeats), especially males, often develop tremor, ataxia, and parkinsonism. These neurological signs are believed to be a result of elevated levels of expanded CGG‐repeat fragile X mental retardation 1 mRNA. The purpose of this study was to determine the prevalence of fragile X mental retardation 1 repeat expansions in a movement disorder population comprising subjects with all types of tremor, ataxia, and parkinsonism. We screened 335 consecutive patients with tremor, ataxia, or parkinsonism and 273 controls confirmed to have no movement disorders. There was no difference in fragile X mental retardation 1 premutation size expansions in the cases compared with controls. Eleven percent of the women with Parkinson's disease had fragile X mental retardation 1 gray‐zone expansions compared with 4.4% of female controls (odds ratio of 3.2; 95% confidence interval, 1.2–8.7). Gray‐zone expansions in patients with other phenotypes were not overrepresented in comparison with controls. Fragile X mental retardation 1 premutation range expansions are not more common in a mixed movement disorder population compared with controls. Our results, however, suggest that fragile X mental retardation 1 gray‐zone alleles may be associated with Parkinson's disease in women. © 2011 Movement Disorder Society |
---|---|
Bibliography: | Full financial disclosures and author roles may be found in the online version of this article. Funding agencies: This work was funded by NS052487 (to D.H.), UL1 DE019583 and RL1 AG032119 (to P.J.H.), M01 RR000051, and a Parkinson Research Center grant from the Parkinson's Disease Foundation. Relevant conflicts of interest/financial disclosures: Nothing to report. ark:/67375/WNG-151PD8T1-7 ArticleID:MDS23755 istex:BD089826896373AE84A4B91D67B6A7E15E6B00D5 This work was funded by NS052487 (to D.H.), UL1 DE019583 and RL1 AG032119 (to P.J.H.), M01 RR000051, and a Parkinson Research Center grant from the Parkinson's Disease Foundation. Nothing to report. Relevant conflicts of interest/financial disclosures Funding agencies ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.23755 |